Nephron Research downgraded Quanterix (QTRX) to Hold from Buy with an $8 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix Completes Acquisition of Akoya Biosciences
- Quanterix Revises Deadlines for Stockholder Proposals
- Quanterix HD-X Simoa gets Class 1 Medical Device registration in South Korea
- Quanterix: Strategic Growth Potential Amid Alzheimer’s Diagnostics and Akoya Merger
- Kent Lake condemns Quanterix’s failure to schedule its 2025 Annual Meeting